Rabi Hanna: First-in-Human CRISPR/Cas12a Therapy in Sickle Cell Disease
oncodaily - Rabi Hanna, Pediatric Blood and Marrow Transplant Program Director, and Chairman at the Department of Pediatric Hematology-Oncology and BMT at Cleveland Clinic, shared a post on LinkedIn: “I am excited […]
AI Summary: A first‑in‑human CRISPR/Cas12a therapy for sickle cell disease has treated initial patients, building on preclinical gene‑editing successes that reversed severe disease in models. The advance underscores rapid translation from lab to clinic and renews hope for durable cures—while reminding everyone that the safety and long‑term durability questions remain firmly on the table.
Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline
esmo - This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence…
AI Summary: ESMO–EURACAN released a comprehensive clinical practice guideline for uveal melanoma covering diagnosis, staging, surveillance and systemic management. The guidance clarifies best practices for multidisciplinary care, risk stratification and therapeutic sequencing, aiming to standardize treatment and follow‑up for a rare but high‑risk ocular tumour.
Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine
Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…
AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.
FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.